Postępy
nasze czasopisma medyczne
New Medicine
Postępy Nauk Medycznych
Medycyna Rodzinna
Nowa Medycyna
Nowa Pediatria
Nowa Stomatologia
oferta Wydawnictwa Borgis
CzytelniaMedyczna.pl
Księgarnia Medyczna Borgis.pl
Księgarnia ogólna DoPoduszki.pl
Newsletter Biuletyn Telegram
Kosmetyki ziołowe
Postępy
Wydawca:
Wydawnictwo Medyczne Borgis

Organ
Sekcji Fitoterapii PTL
Sekcja Fitoterapii Polskiego Towarzystwa Lekarskiego

Leki naturalne o działaniu ochraniającym ściany naczyń krwionośnych

© Borgis - Postepy Fitoterapii 1, s. 47-60
*Katarzyna Karłowicz-Bodalska1, Elżbieta Rudkowska2, Małgorzata Han-Marek3
Leki naturalne o działaniu ochraniającym ściany naczyń krwionośnych
Hasco-Lek S.A. we Wrocławiu
Summary
Key words:
Piśmiennictwo
1. Sirtori C.R.: Aescin: Pharmacology, pharmacokinetics and therapeutic profile. Pharmacol. Res. 2001, 44, 183. 2. Boisseau M.R. et al.: Fibrinolysis and hemorheology in chronic venous insufficiency, a double blind study of troxerutin efficiency. J. Cardiovasc. Surg. 1995, 36, 369. 3. Unkauf M., Rehn D. et al: Investigation of the efficacy of oxerutins compated to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneim.-Forsch. 1996, 46, 478. 4. Blazso G., Gabor M.: Influenze of O-(β-hydroksyethyl)-rutin on the edema-inhibiting effect of indometacin. Acta Pharm. Hung. 1994, 64, 123. 5. Middleton E. J., Kandaswami C.: The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer. The Flavonoids: Advances in research since 1986 (Red. J.B. Harborne) Chapman and Hall, London 1993. 6. Rehn D., Unkauf M. et al: Comparative clinical efficacy and tolerability of oxerutins and horse-chestnut extract in patients with chronic venous insufficiency. Arzneim.-Forsch. 1996, 46, 483. 7. Diebschlag W. et al: Clinical comparison of two doses of O-(β-hydroksyethyl)-rutosides in patients with chronic venous insufficiency. J. Pharm. Med. 1994, 4, 7. 8. Petho A.: Die Wirksamkeit von Benzopyronen bei der posttraumatischen Entzundung. Arzneim.-Forsch. 1981, 31, 1303. 9. Lureau M.A., Glacet-Bernard A., Coscas G.: Occlusion de la veine centrale de la retine bilaterale et anticoagulant circulant. J. Fr. Ophtalmol. 1995, 18, 468. 10. Glacet-Bernard A., Coscas G. et al: A randomized, double-masced study of the treatment of retinal vein occlusion with troxerutin. Am. J. Ophtalmol. 1994, 118, 421. 11. Glacet-Bernard A., Coscas G. et al: Erythrocyte aggregation and retinal vein occlusion. Preliminary data for a randomized study on the efficacy of anti-erythrocyte aggregation (troxerutin) in retinal vein occlusion. Bull Soc. Ophtalmol. Fr. 1989, 89, 1393. 12. Krupiński K., Giedrojć J., Bielawiec M.: Effect of troxerutin on laser-induced thrombus formation in rat mesenteric vessels, coagulation parameters and platelet function. Pol. J. Pharmacol. 1996, 48, 335. 13. Gabor M.: Capillary resistance raising action of venoruton. Acta Pharm. Hung. 1983, 53, 115. 14. Casley-Smith J.R.: Modern treatment of lymphoedema II. The benzo-pyrones. Austral. J. Dermatol. 1992, 33, 69. 15. Patwardhan A., Carlsson K.: The affinity of troxerutin for the venous wall measured by laser scanning microscopy. J. Cardiovasc. Surg. (Torino) 1995, 36, 381. 16. Carlsson K., Patwardhan A: Transport and localisation of troxerutin in the venous wall. J. Mal. Vasc. 1996, 21 (Suppl.C), 270. 17. Cerlek S.: Effect of a benzopyrone compound on liver function. Arzneim.-Forsch. 1977, 27, 611. 18. Preuss-Ueberschar C., Ueberschar S.: Reproduction toxicologic studies on rats following oral administration of benzopyrone preparations. Arzneim.-Forsch. 1984, 34, 1305. 19. Podlewski J.K., Chwalibogowska-Podlewska A.: Leki współczesnej terapii. Fundacja Buchnera, Warszawa 1999. 20. Bombardelli E. et al.: Aesculus hippocastanum L. (review); Fitoterapia 1996, 67, 483. 21. Hänsel R., Keller K: Hager´s Handbuch der Pharm Praxis, T. 4 Springer Verlag, Berlin-Heidelberg-N York 1992. 22. Yoshikawa M., Murakami T. et al.: Bioactive saponins and glycosides. III. Horse chestnut (I): The structures, inhibitory effects on ethanol absorption and hypoglemic activity of escins Ia, Ib, IIa, IIb and IIIa from the seeds of Aesculus hippocastanum L. Chem. Pharm. Bull 1996, 44, 1454. 23. Yoshikawa M., Murakami T. et al.: Bioactive saponins and glycosides. Horse chestnut. Part 2. Structures of escins IIIb, IV, V and isoescins Ia, Ib and V, acylated polyhydroksyoleanane triterpene oligoglycosides from the seeds of horse chestnut trees ( Aesculus hippocastanum L., Hippocastanaceae). Chem. Pharm. Bull 1998, 11, 1764. 24. Yoshikawa M., Murakami T. et al.: Bioactive saponins and glycosides. Horse chestnut. Part 3. Quantitative analysis of escins Ia, Ib, IIa and IIb by means of HPLC. J. Pharm. Soc. Jap. 1999, 119, 81. 25. Morimoto S., Nonaka G.I., Nishioka I: Tannins and related compounds. LIX. Aesculitannins, novel proanthocyanidins with double-bonded structures from Aesculus hippocastanum L. Chem. Pharm. Bull. 1987, 38, 499. 26. Santos-Buelga C., Kołodziej H., Treutter D.: Procyanidin trimers possesing a doubly linked structure from Aesculus hippocastanum. Phytochem. 1995, 38, 499. 27. Lorenz D., Marek M.L.: Das therapeutisch wirksame Prinzip der Rosskastanie ( Aesculus hippocastanum). Arzneim.-Forsch. 1960, 10, 263. 28. Blekic J.: Horse chestnut seeds ( Aesculus hippocastanum L.) in the treatment of phlebopathological disorders: Farmaceutski Glasnik 1996, 52, 145. 29. Guillaume M., Padioleau F.: Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract. Arzneim.-Forsch. 1994, 44, 25. 30. Pittler M.H., Ernst E.: Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Arch. Dermatol. 1988, 134, 1356. 31. Steiner M.: Untersuchung zur odemvermindernden und odemprotektiven Wirkung von Rosskastaniemsamenextrakt. Phlebol. Proktol 1990, 19, 239. 32. Steiner M., Hillemanns H.G.: Venostasin retard in the management of venous problems during pregnancy. Phlebology 1990, 5, 41. 33. Diehm C., Trampisch H.J. et al: Comparison of leg compression stocking and oral horse-chestnut seeds extract therapy in patients with chronic venous insufficiency. Lancet 1996, 347, 297. 34. Vayssairat M., Debure C. et al: Horse-chestnut seed extract for chronic venous insufficiency (letters). Lancet 1996, 347, 1182. 35. Bisler H. et al.: Wirkung von Rosskastaniensamenextrakt auf die transkapillare Filtration bei chronischer venöser Insuffizienz. Dtsch. Med. Wchschr. 1986, 111, 1321. 36. Calabrese C., Preston P.: Report of the results of a double-blind, randomized, single-dose trial of a topical 2% escin gel versus placebo in the acute treatment of experimentally-induced hematoma in volunteers. Planta Med. 1993, 59, 394. 37. Kunz K., Lorkowski G. et al.: Bioavailability of escin after administration of two oral formulations containing aesculus extract. Arzneim.-Forsch. 1998, 48, 822. 38. Schrader E., Schwankl W. et al: Vergleichende Untersuchung zur Bioverfügbarkeit von β-Aescin nach oraler Einmalverabreichung zweier Rosskastaniensamenextrakt enthaltender, galenisch unterschiedlicher Darreichungsformen. Pharmazie 1995, 50, 623. 39. Dittgen M., Zimmermann H. et al: Untersuchung der Bioverfügbarkeit von β-Aescin nach oraler Verabreichung verschiedener Darreichungsformen. Pharmazie 1996, 51, 608. 40. Oschman R., Biber A. et al.: Pharmakokinetik von β-Aescin nach Gabe verschiedener Aesculus -Extract enthaltenden Formulierungen. Pharmazie 1996, 51, 577. 41. Hitzenberger G.: Die terapeutische Wirksamkeit des Rosskastaniensamen-Extraktes. Wiener Med. Wschr. 1989, 17, 385. 42. Henschler D., Hempel K. et al: Zur Pharmakokinetik von Aescin. Arzneim.-Forsch. 1971, 21, 1682. 43. Matsuda M., Li Y. et al: Effects of escins Ia, Ib, Iia, Iib from horse-chestnut the seeds of Aesculus hippocastanum L. on acute inflammation in animals. Biol. Pharm. Bull. 1997, 20, 1092. 44. Matsuda M., Li Y. et al: Antiinflammatory effect of escin Ia, Ib, IIa and IIb from horse chestnut, the seeds of Aesculus hippocastanum L. Bioorg. Med. Chem. Lett. 1997, 7, 1611. 45. Ascher P.W, Paltauf F: Klinische Untersuchungen über die Pharmakodynamik von tritiummarkierten Aescin. Aerztl. Forsch. 1970, 24, 294. 46. Schrodter A., Loew D. et al.: Validity of pharmakokinetic data for β-escin from horse chestnut seed extracts determined by radioimmunological methods. Arzneim.-Forsch. 1998, 48, 905. 47. Willuhn G.: Arnica montana L. – Porträt einer Arzneipflanze. Pharm. Ztg. 1991, 136, 2453. 48. Hall I.H., Lee K.H. et al: Antitumor agents XXX: Evaluation of α-methylene-γ-lactone-containing agents for inhibition of tumor growth, respiration and nucleic acid synthesis. J. Pharm. Sci. 1978, 67, 1235. 49. Hall I.H., Lee K.H. et al: Antiinflammatory activity of sesquiterpene lactones and related compounds. J. Pharm. Sci. 1979, 68, 537. 50. Hall I.H., Starnes C.O. et al: Mode of action of sesquiterpene lactones as anti- inflammatory agents. J. Pharm. Sci. 1980, 69, 537. 51. Lyss G., Schmidt T.J. et al: Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kB. Biol. Chem. 1997, 378, 951. 52. ESCOP. Monographs, Second Ed. 2003. 53. Passreiter C.M., Willuhn G., Roder E.: Tussilagine and isotussilagine: two pyrrolizidine alkaloids in the genus Arnica. Planta Med. 1992, 58, 556. 54. Passreiter C.M.: Co-occurrence of 2-pyrrolidineacetic acid with the pyrrolizidines tussilaginic acid and isotussilaginic acid and their 1-epimers in Arnica species and Tussilago farfara. Phytochem. 1992, 32, 4135. 55. Akihisa T., Yasukawa K. et al.: Triterpene alcohols from the flowers of Compositae and their antiinflammatory effects. Phytochem. 1996, 43, 1255. 56. Zitterl-Eglseer K., Sosa S. et al: Anti-oedematous activities of the main triterpendiol esters of marigold ( Calendula officinalis L.). J. Ethnopharmacol 1997, 57, 139. 57. Vidal-Ollivier E., Elias R. et al: Flavonol glycosides from Calendula officinalis flowers. Planta Med. 1989, 55, 73. 58. Varljen J., Liptak A., Wagner H.: Structural analysis of a rhamnoarabinogalactan and arabinogalactans with immuno-stimulating activity from Calendula officinalis. Phytochemistry 1989, 28, 2379. 59. Dumenil G., Chemli R. et al: Etude des proprietes antibacteriennes des fleurs de Souci Calendula officinalis L. et des teintures meres homeopathiques de C. officinalis L. et C. arvensis L. Ann Pharm. Fr. 1980, 38, 493. 60. Kalvatchev Z., Walder R., Garzaro D: Anti-HIV activity of extracts from Calendula officinalis flowers. Biomed. Pharmacother. 1997, 51, 176. 61. Samochowiec E., Urbańska L. et al: Assessment of the action of Calendula officinalis and Echinacea angustifolia extracts on Trichomonas vaginalis in vitro. Wiad. Parazytol. 1979, 25,77. 62. Gracza L.: Oxygen-containing terpene derivatives from Calendula officinalis. Planta Med, 1987, 53, 227. 63. Bezakova L., Masterova I. et al: Inhibitory activity of isorhamnetin glycosides from Calendula officinalis L. on the activity of lipoxygenase. Pharmazie 1996, 51, 126. 64. Popovic M., Kaurinovic B., et al: Combined effects of plant extracts and xenobiotics on liposomal lipid peroxidation. Part 2. Marigold extract-CCl4/fullerenol. Oxid Commun. 2000, 23, 178. 65. Popovic M., Kaurinovic B. et al.: V. Combined effects of plant extracts and xenobiotics on liposomal lipid peroxidation. Part 1. Marigold extract-ciprofloxacin-pyralene. Oxid Commun 1999, 22, 487. 66. Patrick K.F.M., Kumar S. et al.: Induction of vascularisation by an aqueous extract of the flowers of Calendula officinalis, the European marigold. Phytomed. 1996, 3, 11. 67. Klouchek-Popova E., Popov A. et al: Influenze of the physiological regeneration and epitelization using fractions isolated from Calendula officinalis. Acta Physiol. Pharmacol. Bulg. 1982, 8, 63. 68. Oana L., Mates N. et al: Studies concerning the wound healing action of some medicinal herb extracts. Bulet. Univ. de Stiinte Agricole, Ser. Zootech. Med. Veterin. 1995, 49, 461. 69. Peri de Carvalho P.S., Tagliavini D.G., Tagliavini R.L.: Cutaneous cicatrization after topical application of calendula cream and comfrey, propolis and honey association in infected wounds of kin. Clinical and histological study in rats. Rev. Cienc. Biomed. (Sao Paulo) 1991, 12, 39. 70. Delaveau P., Lalloulette P., Tessier A.M.: Drogues vegetales stimulant l´activite phagocytaire du systeme reticulo-endothelial. Planta Med 1980, 40, 49. 71. Shipochliev T., Dimitrov A., Aleksandrova E.: Study on the inflammatory effect of a group of plant extracts. Vet.-Med. Nauk. (Sofia) 1981, 18, 87. 72. Della Loggia R. et al.: The role of triterpenoids in the topical anti-inflammatory activity of Calendula officinalis flowers. Planta Med. 1994, 60, 516. 73. Della Loggia R., Becker H. et al: Topical anti-inflammatory activity of Calendula officinalis extracts. Planta Med. 1990, 56, 658. 74. Lievre M., Marichy J. et al: Controlled study of three ointments for the local management of 2nd and 3rd degree burns. Clin. Trials and Meta-Anal. 1992, 28, 9. 75. Baranov A.P.: Calendula – Wie ist die Wirksamkeit bei Verbrennungen und Verbrühungen? . Dtsch. Apoth. Ztg. 1999, 139, 2135.

otrzymano/received: 2005-02-14
zaakceptowano/accepted: 2005-10-21

Adres/address:
*Katarzyna Karłowicz-Bodalska
Hasco-Lek S.A.
ul. Żmigrodzka 242E, 51-131 Wrocław
e-mail: hasco@hasco-lek.com.pl

Pełna wersja artykułu Leki naturalne o działaniu ochraniającym ściany naczyń krwionośnych dostępna w Czytelni Medycznej Borgis.
Copyright © Wydawnictwo Medyczne Borgis 2006-2013
Chcesz być na bieżąco? Polub nas na Facebooku: strona Wydawnictwa na Facebooku
do góry strony